Spinal Cord Injury
Patients with subacute spinal cord injury may present electroencephalographic features that predate the onset of neuropathic pain and may serve both as markers and predictors of neuropathic pain.
The diagnostic criteria formulated by the ACTTION-APS Pain Taxonomy working group focus on neuropathic pain from SCI, stroke, and MS.
The therapeutic efficacy of pregabalin in treating 2 types neuropathic pain (NeP) is not influenced by concomitant NeP medications.
Vaporized cannabis had a significant analgesic response over placebo.
Rapamycin is effective in reducing neuropathic pain when administered in the acute and subacute phases following spinal cord injury.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds